A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease

Trial Identifier: EFC17359
Sponsor: Sanofi
Start Date: September 2025
Primary Completion Date: June 2028
Study Completion Date: December 2030

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CANADA, Quebec SHERBROOKE, Quebec, CANADA, J1G 2E8
CHILE, Reg Metropolitana de Santiago SANTIAGO, Reg Metropolitana de Santiago, CHILE, 7500505
UNITED STATES, California San Jose, California, UNITED STATES, 95128
UNITED STATES, Florida MARGATE, Florida, UNITED STATES, 33063
UNITED STATES, Texas Plano, Texas, UNITED STATES, 75093
UNITED STATES, Texas RED OAK, Texas, UNITED STATES, 75154
UNITED STATES, Washington SEATTLE, Washington, UNITED STATES, 98105